Clinical TrialMay 29, 2026, 05:02 PM
Monopar Presents Phase 2 ALXN1840 Results for Wilson Disease
AI Summary
Monopar Therapeutics Inc. announced the presentation of Phase 2 study results for ALXN1840 (tiomolibdate choline) at the European Association for the Study of the Liver (EASL) International Liver Congress 2026. The study, identified as NCT04422431, evaluated the drug's effect on liver pathology and clinical symptoms in patients with Wilson disease. The presentation document was included as Exhibit 99.1 in the 8-K filing.
Key Highlights
- Monopar Therapeutics presented results from a Phase 2 study (NCT04422431).
- The study evaluated ALXN1840 (tiomolibdate choline) for Wilson disease.
- Focus was on liver pathology and clinical symptoms in patients.
- Results were presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2026.
- The presentation was furnished as Exhibit 99.1 to the report.
Price Impact
More from MNPR